BA
OPRX icon

Bridgewater Associates’s OptimizeRx OPRX Stock Holding History

Bridgewater Associates’s Portfolio OPRX Stock Details OPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,197
Closed -$284K – 912
2022
Q3 		$284K Sell
19,197
-26,932
-58% -$532K ﹤0.01% 830
2022
Q2 		$1.26M Buy
46,129
+2,995
+7% +$88.7K 0.01% 761
2022
Q1 		$1.63M Buy
43,134
+10,434
+32% +$462K 0.01% 719
2021
Q4 		$2.03M Buy
32,700
+4,150
+15% +$314K 0.01% 463
2021
Q3 		$2.44M Buy
+28,550
New +$1.79M 0.01% 407

Other funds holding OPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
GIPM
G2 Investment Partners Management New York $549M AUM 179.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridgewater Associates's OPRX Position: Q4 2022 in Review

Bridgewater Associates sold out of OptimizeRx (OPRX) in Q4 2022, closing a stake of 19,197 shares — an estimated $284K sold.

Bridgewater Associates first reported a position in OPRX in Q3 2021 and held it in 5 quarters. The position peaked at $2.44M in Q3 2021. 128 funds tracked by Wall St. Rank hold OPRX as of Q4 2022.

  • Bridgewater Associates reported no remaining OptimizeRx position as of Q4 2022 after selling out during the quarter.
  • Bridgewater Associates sold 19,197 OptimizeRx shares in Q4 2022, an estimated $284K.
  • Bridgewater Associates first reported a position in OptimizeRx in Q3 2021 and held it in 5 quarters.
  • Bridgewater Associates's OptimizeRx position peaked at $2.44M in Q3 2021.
  • 128 funds tracked by Wall St. Rank held OptimizeRx as of Q4 2022.

Based on Bridgewater Associates's 13F filing for Q4 2022, filed 13 Feb 2023.